EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States

Hung-Fu Tseng iD, Lina S Sy iD, Bradley K Ackerson iD, Emily Rayens iD, Jun Wu iD, Yi Luo iD, Yanjun Cheng iD, Jennifer H Ku iD, Leticia I Vega Daily iD, Harpreet S Takhar iD, Jeannie Song iD, Rachel A Cohen und 4 weitere

Clinical Infectious Diseases · 04.02.2026 · 81 (6) · e717-e726

DOI: 10.1093/cid/ciaf329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 23.06.2025. Verfasst von Hung-Fu Tseng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Herpes Zoster, Neuralgia, Postherpetic, Vaccine Efficacy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recombinant zoster vaccine (RZV) was approved for adults aged ≥50 years in the United States to prevent herpes zoster (HZ) and postherpetic neuralgia (PHN). This study evaluated real-world vaccine effectiveness (VE) of RZV in adults aged ≥50 years.

Methods

A cohort study was conducted at Kaiser Permanente Southern California (KPSC). The exposed cohort included members aged ≥50 years who received 1 or 2 RZV doses April 2018 to December 2020. They were matched 1:4 with unvaccinated individuals by age, sex, and race/ethnicity, then followed until December 2022. Adjusted VE (aVE) and 95% confidence interval (CI) were estimated via stratified Cox models for 1 dose and 2 doses against HZ (diagnostic codes B02.xx plus antiviral within 7 days) and PHN (chart review for HZ-related pain persisting >3 months). Stratified aVE by demographic characteristics, immunocompromised status, comorbidities, concomitant vaccination, and overall durability were assessed.

Results

Among N = 102 766 (median age 68 years) who received 2 RZV doses (4 weeks–6 months apart), 48 028 (46.7%) had previously received zoster vaccine live; aVE was 73.9% (95% CI: 71.8%–75.8%) for HZ and 83.7% (95% CI: 75.1%–89.3%) for PHN. VE against HZ was comparable across individuals with concomitant vaccinations and different comorbidities. VE against HZ and PHN remained stable over 4 years post-vaccination. One-dose VE was 60.3% (56.4%–63.9%) against HZ and 45.6% (11.4%–66.6%) against PHN.

Conclusions

Two doses of RZV were effective in preventing HZ and PHN in adults aged ≥50 years, with durable protection. These findings underscore the importance of adhering to the recommended vaccination schedule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes Zoster VaccineHerpes ZosterNeuralgia, PostherpeticVaccine EfficacyHumansMaleFemaleMiddle AgedAgedVaccines, SyntheticUnited StatesAged, 80 and overCohort StudiesVaccinationAdjuvants, Immunologic

Stichwörter der Autor:innen

adult vaccinationherpes zosterherpes zoster vaccinevaccine effectiveness

Substanzen

Herpes Zoster VaccineVaccines, SyntheticAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
  • Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.
  • GSK, Rockville, Maryland, USA.

ORCID-Profile: Hung-Fu Tseng, Lina S Sy, Bradley K Ackerson, Emily Rayens, Jun Wu, Yi Luo, Yanjun Cheng, Jennifer H Ku, Leticia I Vega Daily, Harpreet S Takhar, Jeannie Song, Huifeng Yun, Driss Oraichi, Harry Seifert, Lei Qian

Förderung

  • GSK

Zitieren

APA

Tseng, H. F., Sy, L. S., Ackerson, B. K., Rayens, E., Wu, J., Luo, Y., Cheng, Y., Ku, J. H., Vega Daily, L. I., Takhar, H. S., Song, J., Cohen, R. A., Yun, H., Oraichi, D., Seifert, H., & Qian, L. (2026). Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States. Clinical Infectious Diseases, 81(6), e717-e726. https://doi.org/10.1093/cid/ciaf329

Vancouver

Tseng HF, Sy LS, Ackerson BK, Rayens E, Wu J, Luo Y, et al. Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States. Clinical Infectious Diseases. 2026;81(6):e717-e726. doi:10.1093/cid/ciaf329

BibTeX
@article{Tseng2026,
  author = {Tseng, Hung-Fu and Sy, Lina S and Ackerson, Bradley K and Rayens, Emily and Wu, Jun and Luo, Yi and Cheng, Yanjun and Ku, Jennifer H and Vega Daily, Leticia I and Takhar, Harpreet S and Song, Jeannie and Cohen, Rachel A and Yun, Huifeng and Oraichi, Driss and Seifert, Harry and Qian, Lei},
  title = {Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {e717--e726},
  doi = {10.1093/cid/ciaf329}
}
Kostenlos starten →